1. Home
  2. VTRS vs SF Comparison

VTRS vs SF Comparison

Compare VTRS & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTRS
  • SF
  • Stock Information
  • Founded
  • VTRS 1961
  • SF 1890
  • Country
  • VTRS United States
  • SF United States
  • Employees
  • VTRS N/A
  • SF N/A
  • Industry
  • VTRS Medicinal Chemicals and Botanical Products
  • SF Investment Bankers/Brokers/Service
  • Sector
  • VTRS Health Care
  • SF Finance
  • Exchange
  • VTRS Nasdaq
  • SF Nasdaq
  • Market Cap
  • VTRS 10.6B
  • SF 9.8B
  • IPO Year
  • VTRS N/A
  • SF N/A
  • Fundamental
  • Price
  • VTRS $9.37
  • SF $110.60
  • Analyst Decision
  • VTRS Hold
  • SF Hold
  • Analyst Count
  • VTRS 5
  • SF 9
  • Target Price
  • VTRS $10.40
  • SF $112.38
  • AVG Volume (30 Days)
  • VTRS 9.5M
  • SF 733.0K
  • Earning Date
  • VTRS 08-07-2025
  • SF 07-30-2025
  • Dividend Yield
  • VTRS 5.13%
  • SF 1.66%
  • EPS Growth
  • VTRS N/A
  • SF 19.51
  • EPS
  • VTRS N/A
  • SF 5.24
  • Revenue
  • VTRS $14,330,200,000.00
  • SF $5,030,597,000.00
  • Revenue This Year
  • VTRS N/A
  • SF $8.07
  • Revenue Next Year
  • VTRS $1.85
  • SF $10.55
  • P/E Ratio
  • VTRS N/A
  • SF $21.09
  • Revenue Growth
  • VTRS N/A
  • SF 14.86
  • 52 Week Low
  • VTRS $6.85
  • SF $73.27
  • 52 Week High
  • VTRS $13.55
  • SF $120.64
  • Technical
  • Relative Strength Index (RSI)
  • VTRS 58.40
  • SF 66.15
  • Support Level
  • VTRS $8.84
  • SF $108.16
  • Resistance Level
  • VTRS $9.29
  • SF $111.14
  • Average True Range (ATR)
  • VTRS 0.22
  • SF 2.20
  • MACD
  • VTRS -0.01
  • SF -0.15
  • Stochastic Oscillator
  • VTRS 88.33
  • SF 89.29

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

About SF Stifel Financial Corporation

Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.

Share on Social Networks: